DOI: https://doi.org/10.36347/sasjm.2026.v12i04.020

Pages: 344-347

To evaluate therapies available for the treatment of irritable bowel syndrome, and provide consensus recommendations for their use, a total of 51 double-blind clinical trials using bulking agents, prokinetics, antispasmodics, alosetron, tegaserod and antidepressants were selected. This study took place at the Department of Medicine at Medical College for Women and Hospital, Ibn Sina Diagnostic and Consultation Centre, Uttara, Dhaka, Bangladesh with symptoms of IBS, from June 2021 to July 2023. This study recommends the use of tegaserod for women with irritable bowel syndrome with constipation and alosetron for women with severe irritable bowel syndrome with diarrhoea. Antidepressants can be beneficial for irritable bowel syndrome with diarrhoea patients with severe symptoms. Loperamide can be recommended in painless diarrhoea. Evidence is weak to recommend the use of bulking agents in the treatment of irritable bowel syndrome with constipation.